<DOC>
	<DOCNO>NCT00189137</DOCNO>
	<brief_summary>The purpose study explore sarcoma affected side effect new combination chemotherapy drug ( gemcitabine docetaxel ) compare standard combination chemotherapy drug , ifosfamide doxorubicin .</brief_summary>
	<brief_title>Evaluation Side Effects Relative Activity Two Chemotherapy Regimens Treatment Soft Tissue Sarcoma</brief_title>
	<detailed_description>The purpose study explore relative activity toxicity new combination chemotherapy drug , gemcitabine docetaxel , compare standard combination chemotherapy drug , ifosfamide doxorubicin . Ifosfamide Doxorubicin , give combination , recognize standard care type sarcoma . Both gemcitabine docetaxel approve US Food Drug Administration ( FDA ) treatment cancer ( cancer pancreas , lung ) patient cancer treat either gemcitabine docetaxel experience shrinkage tumor improvement symptom . However , neither gemcitabine docetaxel approve sarcoma , combination gemcitabine docetaxel standard treatment advance sarcoma .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>evidence metastasis soft tissue sarcoma intermediate high histologic grade great 5 cm Zubrod performance status 1 good age 10 old clear cell , alveolar soft part , Ewing 's rhabdosarcoma , undifferentiated small cell Kaposi 's prior chemotherapy nephrectomy active unstable angina pectoris concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>